Intellia Therapeutics
NTLA
328 hedge funds and large institutions have $2.44B invested in Intellia Therapeutics in 2026 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 140 increasing their positions, 80 reducing their positions, and 28 closing their positions.
123% more call options, than puts
Call options by funds: $55.3M | Put options by funds: $24.8M
96% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 28
75% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 80
72% more capital invested
Capital invested by funds: $1.41B → $2.44B (+$1.03B)
9.48% more ownership
Funds ownership: 93.49% → 102.97% (+9.5%)
8% more funds holding
Funds holding: 304 → 328 (+24)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$63.4M |
| 2 |
BlackRock
New York
|
+$45.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.9M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$33.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.51M |
| 2 |
Capital Fund Management (CFM)
Paris,
France
|
-$6.04M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.68M |
| 4 |
Jane Street
New York
|
-$5.2M |
| 5 |
Morgan Stanley
New York
|
-$4.89M |
NTLA Hedge Fund Activity: Q2 2026 in Review
328 institutional investors reported a position in Intellia Therapeutics (NTLA) for Q2 2026, worth a combined $2.44B — up 72% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new NTLA positions and 28 closed out — a net gain of 27 holders — while 140 added to existing stakes and 80 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $63.4M. The largest seller was UBS Group, cutting an estimated $7.51M.
- 328 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2026, up from 304 in Q1 2026.
- Funds reported $2.44B of Intellia Therapeutics stock for Q2 2026, up 72% quarter-over-quarter.
- 55 funds opened new Intellia Therapeutics positions in Q2 2026 and 28 closed out, a net change of +27 holders.
- The largest Intellia Therapeutics buyer in Q2 2026 was RA Capital Management, an estimated $63.4M added.
- The largest Intellia Therapeutics seller in Q2 2026 was UBS Group, an estimated $7.51M sold.
Based on aggregated 13F filings for Q2 2026.